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Abstract
Background: Immune thrombocytopenic purpura (ITP), a condition characterized by
autoimmune-mediated platelet destruction and suboptimal platelet production, is associated with
symptoms such as bruising, epistaxis, menorrhagia, mucosal bleeding from the gastrointestinal and
urinary tracts and, rarely central nervous system bleeding. The aim of this research is to develop a
conceptual model to describe the impact of ITP and its treatment on patients' health-related quality
of life (HRQoL).
Methods: A literature search and focus groups with adult ITP patients were conducted to identify
areas of HRQoL affected by ITP. Published literature was reviewed to identify key HRQoL issues
and existing questionnaires used to assess HRQoL. Focus group transcripts were reviewed, and
common themes were extracted by grouping conceptual categories that described the impact on
HRQoL.
Results: The literature synthesis and themes from the focus group data suggest that decreased
platelet counts, disease symptoms, and treatment side effects influence multiple domains of HRQoL
for ITP patients. Key areas affected by ITP and its treatments include emotional and functional
health, work life, social and leisure activities, and reproductive health.
Conclusion: ITP affects various areas of HRQoL. This conceptual model will help inform the
evaluation of therapeutic strategies for ITP.
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Immune thrombocytopenic purpura (ITP) is an autoim-
mune disorder characterized by accelerated platelet
destruction and suboptimal platelet production that leads
to reduced peripheral blood platelet counts [1-3]. The eti-
ology of ITP is poorly understood [4]. The estimated
annual incidence of adult ITP ranges from 0.6 to 6.6 cases
per 100,000 adults [1,4-6]. Women are affected dispro-
portionately, with a female to male ratio of nearly two to
one [1]. ITP in adults infrequently remits spontaneously
[1] and, although the course of the disease is unpredicta-
ble, ITP is rarely fatal, if appropriately managed [4,7].
The physical signs and symptoms of ITP can vary by
patient. Some patients suffer from major bleeding that
requires immediate attention [8], while other patients
with ITP present with few symptoms apart from an
increased tendency to bruise or have mucosal bleeding.
The degree of bleeding throughout the course of the dis-
ease is largely dependent on the patient's platelet count,
although other factors certainly contribute. Those with the
lowest platelet counts are at the greatest risk for bleeding
which can include menorrhagia, gastrointestinal or uri-
nary tracts bleeding and, in rare cases, central nervous sys-
tem or intracranial bleeding [8]. ITP patients with
persistently very low platelet counts (<10 × 109/L) despite
treatment, are at risk for both fatal and non-fatal bleeding
events [9]. Specifically, Cohen, et al. estimated that five-
year mortality rates for ITP patients with persistent low
platelet counts (<30 × 109/L) ranged from 2.2% for
patients under 40 years of age and 47.8% for patients
older than 60 [7].
Treatments currently approved for use in ITP include cor-
ticosteroids, intravenous immunoglobulins (IVIG), anti-
D immunoglobulins, splenectomy, rituximab, and cyclo-
phosphamide [1,2,10,11]. Standard first line therapy for
those with low platelet counts consists of medications
such as oral corticosteroids and intravenous immu-
noglobulins. Patients who do not respond to medical
therapies, who relapse after response to therapies, or who
require potentially intolerable doses of medical therapies
to achieve platelet counts high enough to prevent bleed-
ing usually undergo splenectomy, if the patient is a suita-
ble candidate [11]. Patients who do not respond to or
relapse after splenectomy may be treated with a wide spec-
trum of treatments including corticosteroids, rituximab,
danazol, immunosuppressants (e.g. cyclosporine or myc-
ophenolate mofitil) or cytotoxic agents (e.g. cyclophos-
phamide or azathioprine), each with their own side effects
[1,2,4,8]. These treatments have variable effectiveness in
treating ITP, and may often be associated with substantial
side effects [4]. The one year incidence of diabetes, obes-
ity, and gastrointestinal bleeds are two times higher, and
the one year incidences of myocardial infarction and oste-
oporosis are three times higher in ITP patients receiving
treatment with corticosteroids than age- and gender-
matched non-ITP patients [12].
Although splenectomy results in long-term disease con-
trol in about two-thirds of patients, the long-term out-
come in the individual patient is unpredictable [13].
Further, splenectomy patients are at a slightly increased
risk for overwhelming sepsis [13]. Currently approved
medical treatments for ITP can cause major adverse reac-
tions [14]. For instance, rituximab infusions may cause
chills, fever, or severe anaphylactoid reactions [2]; dana-
zol is associated with rash, masculinizing symptoms and
liver toxicity [1]; cytotoxic agents may cause cytopenias,
gastrointestinal symptoms and, rarely secondary malig-
nancies [8]; and immunosuppressive agents can subject
the patient to increased risk of infection [1]. Patients and
physicians need to consider both the impact of symptoms
of ITP as well as the impact of treatment side effects when
making decisions about treatment. It is, therefore, impor-
tant to incorporate the patient's perspective in decisions
regarding the management of their ITP.
Patient-reported outcomes (PROs) provide information
from the patient's perspective. PROs have become impor-
tant tools for understanding the effects of both disease
and treatments for various diseases. Health-related quality
of life (HRQoL) is the most commonly assessed PRO in
clinical research. Both the US Food and Drug Administra-
tion (FDA) and the European Agency for the Evaluation of
Medicinal Products (EMEA) have emphasized the value of
PRO measures in identifying and quantifying the impact
of a disease or its treatments on daily life, physical, psy-
chological and social functioning, and well-being [15,16].
Further, these agencies have recently indicated that devel-
oping an appropriate and clearly defined conceptual
model is a critical step in the development and use of PRO
measures [15,16].
In an earlier paper, Mathias, et al. presented the develop-
ment and validation of an instrument, the ITP-Patient
Assessment Questionnaire (ITP-PAQ), to assess HRQoL in
ITP patients [17,18]. However, the conceptual model link-
ing the biological and physiological variables of ITP to
HRQoL was not included. The aim of this research is to
develop a conceptual model to describe the impact of ITP
and its treatment on patients' HRQoL.
Methods
This project uses the model proposed by Wilson and
Cleary [19] as a guide for illustrating how biologic and
physiologic variables can lead to changes in general health
perceptions and overall HRQoL in patients with ITP. Two
data sources were used: existing literature and patient con-
tribution. Two literature searches were conducted to iden-Page 2 of 14
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from ITP patients regarding their disease or treatment.
Also, focus groups were held to solicit patients' input. The
focus group format allowed for dynamic responses that
built upon the contributions of each patient. Both data
sources were referenced in developing a comprehensive
conceptual model for HRQoL in adult ITP patients.
Literature review
The purpose of the literature reviews was to summarize
relevant issues for ITP patients, identify existing HRQoL
questionnaires used with ITP patients, describe the clini-
cal aspects of chronic ITP, and describe the impact of ITP
and its treatments on patients' HRQoL. Search terms in
MEDLINE between the years 1997 and 2007 included
"idiopathic thrombocytopenic purpura," "immune
thrombocytopenic purpura" or "ITP" and "outcomes,"
"well being," "quality of life," or "questionnaire". The
searches were limited to adults (>18 years old). Although,
a literature search was conducted at the time of the focus
groups in 2001, a supplemental search was conducted
now to capture more recent work.
Published abstracts were reviewed to identify those that
focused on the effect of ITP or ITP treatments. In addition,
new PRO questionnaires that were developed after 2001,
one of which was the outcome of the focus group inter-
views employed here, were reviewed for relevance.
Research reports that did not focus solely on ITP, e.g. stud-
ies on general hematologic disorders, were excluded from
the review. All remaining publications were retrieved and
reviewed to identify aspects that affect HRQoL, including
symptoms of the disease and side effects of treatments.
Focus groups
Patients
In June 2001, moderated traditional (in-person) focus
groups were conducted in New York City, NY (NY), Okla-
homa City, OK (OK), and San Diego, CA (CA) to identify
the important issue areas for ITP patients. The informa-
tion from these focus groups was initially used to develop
the ITP-Patient Assessment Questionnaire (ITP-PAQ), an
ITP-specific HRQoL questionnaire that has since been val-
idated [17,18]. For each focus group, patients were
recruited at a local academic-based tertiary care center.
The study protocol was prepared and approved by a cen-
tral Institutional Review Board, and all patients provided
written informed consent to participate. Patients were eli-
gible if they were at least 18 years old, had active ITP, and
were willing to participate in the focus group. Although
there were no specific clinical or medical history require-
ments for participation in the focus groups, clinicians at
each site invited patients who had active disease and
required treatment and/or frequent monitoring. Each
focus group consisted of 7 or 8 patients, with at least one
male patient in each group. A trained moderator used a
semi-structured interview format to direct the discussion,
encourage interaction among members of the focus
group, and ask clarifying questions. The focus groups
lasted between 2–3 hours and were audio taped and tran-
scribed. Participants were provided with an honorarium
for their time.
Data analysis
A project team member divided the transcripts from each
focus group into individual units of text. The text units
were segments of continuous speech ranging in size from
phrases to entire paragraphs that referred to some effect of
ITP on the individual's life. No analytic software was used
for the qualitative analysis.
Although each focus group was transcribed verbatim, the
transcription method was not standardized across focus
group location. For instance, each time a focus group par-
ticipant spoke during the OK and CA focus groups, the
transcriber identified the participant by a patient identi-
fier. However, none of the NY participants were similarly
identified. Therefore, when evaluating the frequency with
which individual patients reported a specific theme, only
the OK and CA responses were considered. For the NY
focus group responses it was simply assessed whether or
not patient(s) in the focus group reported the concept.
Each text unit was given equal weight, except in instances
where the same patient reported the same concept during
the CA and OK focus groups. In such cases, the text units
were grouped and counted only once per patient. After the
text units were identified and – when possible – catego-
rized by patient, a second project team member grouped
the text units into sub-categories by clustering groups of
identical text units, or ones that addressed essentially the
same concept. The sub-categories were then grouped into
primary conceptual categories. A grid was developed to
schematically identify common factors among the
themes.
Conceptual model
Although ideally, the development of a conceptual model
would precede the development of a questionnaire, in
this instance the activities were not carried out in that
sequence. The focus groups and literature review that were
conducted in 2001 were used for item generation in the
development of the ITP-PAQ in the absence of a concep-
tual model [17]. We used the focus groups and an updated
literature review to develop the structure and content of
the conceptual model, in an approach similar to the one
described as simultaneous concept development by Finf-
geld-Connett [20]. The simultaneous concept develop-
ment approach assumes that the elements of the
conceptual model are likely to be closely linked and thePage 3 of 14
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model.
The common themes identified in the information from
the literature and text units from the focus groups drove
the formation of the initial conceptual model. The rela-
tionship between the sub-categories and primary concep-
tual categories were based on the patient attributions. The
initial conceptual model was submitted for review at a
consensus group meeting where the research team and
expert consultants and clinicians reviewed the categories
and the proposed relationships to refine the interrelation-
ships among the categories. The categories and relation-
ships were then organized into a final conceptual model
representing the impact of ITP on HRQoL.
Results
Literature review
The current literature search identified 72 articles of which
thirty-three citations were excluded because ITP was not
an inclusion criterion for the presented research. Figure 1
describes the categorization of the search results. As illus-
trated in the figure, most of the articles reviewed focused
on the outcomes associated with treatment including
comparisons between multiple types of treatments
(including corticosteroids) [21,22], open or laparoscopic
splenectomy [23-31], intravenous anti-D immunoglobu-
lin [32,33], rituximab [14], intravenous immunoglobulin
(IVIg) [34], etanercept [35], combination chemotherapy
regimens [36], or summary reviews of treatments [37-40].
The remaining articles pertained to a variety of aspects
related to ITP, including pregnancy outcomes [41-47],
country-specific retrospective chart reviews [48-51], or lit-
erature reviews [13,52-54].
The physical manifestation, the risks, and the clinical
aspects of the disease are well characterized in the litera-
ture. Some studies mentioned the specific physical signs
and symptoms of ITP, such as bleeding and bruising
[21,54,55]. The degree, frequency, or severity of bleeding
ITP HRQoL literature review flowchartFigure 1
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often reported [25,32,41-43,48,53]. However, the litera-
ture search yielded few research reports that collected data
directly from the patients or that described the impact of
disease on the patients' HRQoL. We describe each study
identified in the literature search that incorporated PRO
data in characterizing ITP.
In a 2002 study of 28 ITP patients receiving repeated infu-
sions of anti-D, Cooper, et al. asked patients to complete
a study-specific six-item questionnaire to assess whether
there was a change in HRQoL from the baseline assess-
ment [32]. The six questions included one item on each of
the following concepts: well-being compared to baseline,
general health compared to the previous year, interference
of physical or emotional problems with social activities,
and three items related to energy including how often the
patient "has a lot of energy", "feels full of pep", and "feels
tired". At the 6-month follow-up assessment, patients
reported a decrease in well-being compared to their base-
line response. At the 12 and 18-month follow-up assess-
ments, patients reported an improvement in general
health compared to the previous year, and a reduction in
the interference of physical or emotional problems with
social activities. There were no significant changes over
time in the more specific questions about energy level.
The search also yielded a few articles that focused prima-
rily on the use of patient questionnaires. In 2007, Matz-
dorff and Arnold surveyed 91 patients with ITP in
Germany [55] to determine whether they had been treated
according to the 1996 ASH guidelines. Through the sur-
vey, the researchers assessed personal and disease history,
treatment history, and informational and decision-mak-
ing history. The most common treatment patients
received was corticosteroids (94%), followed by IV Ig
(56%). Seventy-five percent of the patients reported expe-
riencing some side effects from corticosteroid treatment,
including weight gain (58%), moon face (48%), depres-
sion and anxiety (35%), and restlessness and insomnia
(22%).
In another study Cohen, et al. modeled quality-adjusted
life expectancy in ITP. They made assumptions regarding
utility values based on the age- and sex-adjusted Quality
of Well Being Index utility values reported for other
patient populations, because values were not available for
ITP patients. Cohen, et al. predicted that a 30-year old
woman remaining thrombocytopenic due to ITP would
lose 20.4 years (14.9 quality-adjusted life years) of her
potential life expectancy [7].
Zhou, et al. used the Medical Outcomes Study Short Form
36 Health Survey (SF-36) to measure HRQoL in 236
adults with ITP in a cross-sectional study [56]. In addition
to the SF-36, a study questionnaire asked patients to rate
their fear of bleeding on a 4-point likert scale. Most of the
patients (88.1%) reported some fear of bleeding. The
authors found that this fear had a significant detrimental
impact on SF-36 scores. They also found that patients who
had been diagnosed with ITP more than 6 months ago
had lower HRQoL than patients diagnosed less than 6
months ago.
Mathias, et al. reported on the development and psycho-
metric validation of the 44 item ITP-PAQ to measure
HRQoL [17]. The ITP-PAQ was developed based on find-
ings from the published literature, existing question-
naires, expert clinical opinion from leading
hematologists, and input from focus groups of ITP
patients. The final questionnaire contains 10 scales,
including Symptoms, Bother-Physical Health, Fatigue/
Sleep, Activity, Fear, Psychological Health, Work, Social
Activity, Women's Reproductive Health, and Overall
QOL.
Recently, McMillan, et al. reported on the comparison of
SF-36 scores of ITP patients with SF-36 scores of the gen-
eral US population and the scores of patients with hyper-
tension, arthritis, diabetes mellitus, congestive heart
failure, missing or paralyzed limb, or cancer [57]. These
authors found significantly lower scores in patients with
ITP compared to the general US population for nearly all
the SF-36 domains (except mental health). They also
found that the physical impact of chronic ITP on HRQoL
was similar to that of diabetes and greater than that of
hypertension, arthritis, or cancer. They acknowledge that
distinguishing whether ITP or the treatment of ITP con-
tributes to the reduction of HRQoL can be challenging,
especially with a generic instrument like the SF-36.
Focus groups
Twenty-three patients (OK:8, CA:7, NY:8) participated in
the focus groups, 16 (70%) were women (OK:5, CA:6,
NY:5). No additional demographic data were collected.
Focus group data used to shape the conceptual model are
summarized in Tables 1 and 2. Table 1 contains the com-
prehensive list of themes reported by the patients. Each
theme is grouped into a primary conceptual category (a-
g). Table 2 indicates the emphasis given to each primary
conceptual category during the focus group discussions.
Not surprisingly, based on the patients' attributions (a)
symptoms, e.g., bleeding and bruising, that result from
low platelet counts; and, (b) side effects of treatment, e.g.,
weight gain and mood swings, were mentioned as signifi-
cant impairments to overall HRQoL. These two categories
were considered the main determinants of HRQoL
changes for patients with ITP.Page 5 of 14
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Table 1: Comprehensive list of themes
a. Signs and Symptoms c. Emotional Health
Fatigue Relationships
▪ Inability to get out of bed ▪ Spouse
▪ Limits daily activities ▪ Family
Bleeding ▪ Friends
▪ Blood blisters ▪ Children
▪ Bleeding from gums Fear, Stress, & Anxiety
▪ Nose bleeds ▪ Fear of accidents
▪ Embarrassment ▪ Fear of intracranial bleeding
Bruising ▪ Fear of low platelet counts
▪ Bruises that never go away ▪ Fear of dying
▪ Bruises all over legs ▪ Financial stress
▪ Petechia ▪ Stress contributes to low platelet levels
Other ▪ Anxiety about low platelet levels
▪ Migraines ▪ Anxiety medical profession's lack of knowledge
▪ Visual impairment Depression, Isolation, oss of Control
▪ Joint aches ▪ Seek therapy or counseling
▪ Suicidal
b. Treatment Effects ▪ Go off by myself
Steroids ▪ Feels alone
▪ Mood swings ▪ Family/friends don't understand ITP
▪ Weight gain ▪ Resentment towards health professionals
▪ Anger ▪ Feels pressure to be strong
▪ Anxiety Mood & Self-Conscious
▪ Trouble sleeping/insomnia ▪ Mood swings
▪ Round face ▪ Choice of clothing limited due to bruising
▪ Lump in back ▪ Bothered by needle marks
Other treatments ▪ Avoid mirrors
▪ Headaches ▪ Embarrassed by bleeding
▪ Hair loss ▪ Self-conscious about bruising
▪ More susceptible to colds and fungal infections
f. Social and Leisure Activities
d. Functional Health Sports/exercise/physical activities
Daily Activities ▪ Unable to go to the gym
▪ Housework, including cooking ▪ Unable to do sports, boxing, martial arts, skydiving, climbing, dancing
▪ Fatigue limits daily activities Leisure activities
▪ Extreme care in doing simple tasks ▪ Unable or too tired to go out with friends
Changes in Lifestyle Travel is limited or more difficult
▪ Inability to plan for the future Feelings of isolation due to physical and emotional effects of ITP
▪ Reduction in risk-taking activities Social stigma
▪ Hide the severity of disease from family ▪ People suspect spousal or parental abuse due to bruising
Sleep
▪ Restlessness g. Reproductive Health
▪ Not comfortable Women's Reproductive Issues
▪ Tired, but unable to sleep ▪ Hysterectomy because of bleeding
▪ Heavy menstrual bleeding
e. Work Life ▪ Inability to have children
Absences Sex
▪ Permanent disability ▪ Bruising
▪ Frequent absences due to illness, and due to medical visits ▪ Bleeding
▪ Unemployed ▪ Reduced libido
Change in Attitudes
▪ Work to support family
▪ Work in a low risk environment
▪ Work is a lower priority
▪ Work is not as satisfying
Productivity
▪ Fatigue hinders work
▪ Working part-time due to absences
Career advancement
▪ Lost promotions
▪ Unable to pursue desired career
▪ Change career
Health and Quality of Life Outcomes 2008, 6:13 http://www.hqlo.com/content/6/1/13Also, Table 2 provides details about the sub-categories
included in each of the primary conceptual categories. The
table indicates whether the sub-category was mentioned
during each of the focus groups and provides the number
(and percentage) of patients that mentioned the sub-cate-
gories in the CA and OK focus groups. Although most sub-
categories were mentioned during all focus groups, a few
differences emerged which are highlighted below.
Conceptual model
Based on the findings from the literature review and focus
groups, we developed a conceptual model as presented in
Figure 2. Following the Wilson & Cleary model [19], the
biologic variable (platelet count) and the main determi-
nants (signs and symptoms of ITP and the treatment
effects) were placed on the left side of the causal model.
This was followed by the domains of emotional and func-
tional health, work life, social and leisure activities, and
reproductive health. This model proposes that symptoms
of ITP and side effects of its treatment lead to a worsening
in HRQoL by adversely affecting certain domains. Below
we discuss each component of the model.
Biological variables
Platelet counts, with or without the presence of any signs
or symptoms, are often the only determinant of treatment
decisions [54,58] and are also used to establish whether
the patient has responded to treatment and whether the
response is considered complete, partial, or minimal [54].
Platelet counts are inversely correlated with bleeding out-
comes, and are of utmost concern to patients. Patients
that had undergone splenectomy emphasized that gener-
ally their platelet counts rose immediately following the
procedure, but then the platelet counts leveled off or
dropped in the months and years post-surgery. The poten-
tial for and actual drops in platelet counts may cause emo-
tional distress. Some patients report that it is "like a
rollercoaster" or that their platelet levels "go way up and
then way down". Table 3 contains further examples of ver-
batim patient quotes on platelet counts and other discus-
sion areas from the focus group participants.
Table 2: Frequency of Reports of Primary Conceptual Categories and Sub-Categories from ITP Focus Groups
OK NY CA N = 15 (%)*
a. Signs and Symptoms 14 (93%)
Fatigue + - + 14 (93)
Bleeding + + + 8 (53)
Bruising + + + 8 (53)
Other + + + 8 (53)
b. Treatment Effects 13 (87)
Steroids + + + 13 (87)
Other treatments + + + 8 (53)
c. Emotional Health 14 (93)
Fear, stress & anxiety + + + 11 (73)
Relationships + + + 7 (47)
Depression, isolation, & loss of control + + + 7 (47)
Mood & self-consciousness + + + 7 (47)
d. Functional Health 13 (87)
Daily activities + + + 11 (73)
Sleep + + + 9 (60)
Changes in lifestyle + + + 7 (47)
e. Work 13 (87)
Absences + + + 10 (67)
Changes in attitudes - + + 5 (33)
Career advancement + + + 3 (33)
Productivity + + + 4 (27)
f. Social and Leisure 10 (67)
Sports/exercise/physical activity + + + 5 (33)
Leisure activities + + + 5 (33)
Social Stigma + - + 4 (27)
Travel + + + 3 (20)
g. Reproductive Health 10 (67)
Sex + + + 9 (60)
Women's reproductive issues + + + 8 (53)
+ = theme present in focus group
- = theme not present in focus group
* based on data from OK and CA focus groups onlyPage 7 of 14
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ated with platelet counts support Zhou, et al.'s assessment
that the fear of bleeding due to low platelet counts may
itself interfere with patients' HRQoL [56].
Main determinants
Signs and Symptoms
Table 2a indicates the most commonly reported signs and
symptoms that patients attributed to ITP. One patient in
the CA focus group characterized fatigue as follows,
"Fatigue is [the] number one [issue] for me." Moreover, as
shown in Table 2a, fatigue was reported by over 90% of
the patients in the CA and OK focus groups. Interestingly,
fatigue was not mentioned in the NY focus group.
Other very commonly reported symptoms were bleeding
and bruising. In describing her bleeding, one patient said
"I guess the worst was probably ... when I had a lot of
bleeding in my mouth. I hate when I taste blood."
Another patient described her bruising by stating, "I'm
bruised all the time and I'm pretty used to it now. It's very
annoying, but it's just a way of life now."
Although they did not provide details or rationale for the
selection of the items, Cooper, et al.'s choice of questions
suggests that fatigue was a primary concern for ITP
patients [32]. Other reports in the literature suggest that
anemia, a likely cause of fatigue, is common in ITP
patients, especially in the presence of bleeding [48]. In
particular, Cines and Bussel provide anecdotal evidence of
a young female patient experiencing extreme fatigue at
platelet counts <50,000 × 109/L [59].
Treatment Effects
Table 2b indicates that the most commonly reported
adverse effects of ITP treatment were attributed to the use
of steroids. The focus group patients reported numerous
effects of corticosteroid treatment, including anger,
insomnia, mood swings, and weight gain (see Table 1 for
more detail). Most patients in the CA and OK focus
groups reported that the adverse effects of steroids nega-
tively impacted their lives. One patient summarized her
feelings about steroids by stating, "I won't take it and my
count is 3 and I won't take it because my quality of life
means too much and I already don't feel good." Some
patients also expressed increased concern over susceptibil-
ity to infection as a result of splenectomy. For instance, a
female patient in the CA focus group stated "I'm very sus-
ceptible to illness, colds, and lung problems. I've become
fanatical with germs. I don't touch things." Patients also
articulated some concern about the decision to proceed
with a splenectomy when remission following splenec-
tomy is far from certain. Similar observations were
reported in the findings of Matzdorff and Arnold [55].
HRQoL domains
Emotional Health
Patients frequently mentioned "anxiety", "depression",
and "fear" to describe their feelings about their symptoms.
Many patients reported that ITP and its symptoms had an
effect on their personal relationships. Table 2c shows that
Conceptual model for HRQoL in patients with ITPFigure 2
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Table 3: Direct quotes from ITP patient focus groups
Biological Variables ▪"like a rollercoaster"
▪" [platelet levels] go way up and then way down"
▪ "[The fact that] you're sick now but you'll be okay in 2 days or 2 weeks... was a particularly difficult area for me to 
handle."
▪ "[After splenectomy] my platelet count went up to 500,000 right after splenectomy, a month later it was back down 
to the teens."
Main Determinants
Signs & Symptoms ▪ "Fatigue is [the] number one [issue] for me."
▪ "I guess the worst was probably ... when I had a lot of bleeding in my mouth. I hate when I taste blood."
▪ "I'm bruised all the time and I'm pretty used to it now. It's very annoying, but it's just a way of life now."
▪ "I've had about three really heavy duty nosebleeds lasting several days and you just have to immobilize yourself and 
hope that the clot will finally hold."
▪ "I get bruises now and then. I do have petechia most of the time on my legs"
Treatment Effects ▪ "I won't take it [steroids] and my count is 3 and I won't take it because my quality of life means too much and I 
already don't feel good."
▪ "I'm very susceptible to illness, colds, and lung problems. I've become fanatical with germs. I don't touch things."
▪ "It's like rocket fuel. All of you know who've done steroids, it's terrible stuff. I think steroids are the worst. steroids 
were worse than the chemo drugs were."
▪ "If I would have heard 50/50 [chance of success/failure] I wouldn't have done it. That 70/30 sounded really good to 
me."
HRQoL Domains
Emotional Health ▪ "The thing about families is they look at you and expect to see you being strong. I feel like they expect me to be able 
to deal with this."
▪ "The worst part about it is the emotional strain that was put on everyone around me."
▪ "There [are] times that I won't go to the doctor because I know that I can't afford to go."
▪ "I have that fear [of accidents]. I always make the sign of the cross because I know if I get banged up I'm gonna bleed."
▪ "When you're in a flare you just feel off in a corner by yourself and you're isolated from everyone."
Functional Health ▪ "I get so tired I can't even move."
▪ "I never sleep through the night. It's just restlessness and you're not comfortable."
▪ "You're limited. You don't do what you used to do to the same degree and you'd still like to do that but you can't do 
it."
▪ "When cooking...you have to be very careful. You have to really take your time when you're cutting."
Work Life ▪ "I loved working but the fact that I have to sleep when I'm not working makes me want to work less so that I can do 
something besides sleep."
▪ "Now I'm a technical writer, which has no [bleeding] risk at all. I just sit at the computer and type. I really don't like 
it, but I don't have too many options."
▪ "I had to take off a lot to go to the hospital to get the treatment."
▪ "I wanted to be a nurse but I couldn't because I had ITP."
▪ "Working part-time."
Social & Leisure Activities ▪ "My friends think I'm crazy because I won't go the movies with them on a Friday night. I'm just so exhausted when I 
get home. I don't have the energy to get dressed and go to a movie."
▪ "My bruising bothers me especially in the summertime when I can't [go swimming] because I'm always bruising and 
people look at you funny."
▪ "I've had co-workers and friends ask me if my husband was beating me."
▪ "When you're bruising, especially during the summer, and you have to go outside and you're so self conscious 
because you know what people are thinking because they automatically just assume, oh boy she's been beat."
▪ "Well, I find myself more reluctant about meeting new people because I have so many bruises so often."
▪ "I don't go jumping off planes. I don't even want to swim in the water. I just don't want to get hurt. I'm very fragile 
now."
▪ "I said, Don't look at me to go anywhere. I'm not leaving New York."
▪ "I always take out traveler's insurance now for cancellations."
▪ "We used to do extensive traveling and we've limited that down to a week or less at a time any more and we don't 
do as many of them as we used to."
▪ "With my grandchildren, they want to jump on me. They want to do a lot of things. I want to do a lot of things with 
them. My daughter tells them 'Don't jump on Grandma. Don't pull her hair. Be careful.' That really bothers me."
Reproductive Health ▪ "When I first got ITP I thought that I couldn't have children. And then my gynecologist told me that I could have 
children while taking prednisone. All those years my hematologist made me think I couldn't have children."
▪ "You have to be cautious...If I had sexual relations [I was afraid] something was gonna happen to me."
▪ "I don't feel sexy. I don't know if it's the weight gain or if it's the stigma of being sick."
▪ "When my platelets are low I say "Stay away." [regarding sex]"
▪ "Much heavier [periods] and lasted anywhere from 6 to 9 weeks"
▪ "Now on the prednisone my desire has went [sic] down considerably. I swear I used to be sexually active 4 or 5 
nights a week, now it's once or twice a month."
Health and Quality of Life Outcomes 2008, 6:13 http://www.hqlo.com/content/6/1/13emotional health concerns were an issue discussed in all
focus groups, with a similar number of patients expressing
concern over relationships, mental health, and self-con-
sciousness. The emotional concerns appeared to affect
women differently than men. Men were particularly con-
cerned with their ability to provide for their families and
their need to appear stoic. In contrast, women discussed
the protective nature of family and friends and the effect
their illness had on others. This is illustrated by a male
participant in the OK focus group commenting, "The
thing about families is they look at you and expect to see
you being strong. I feel like they expect me to be able to
deal with this." A female participant in the same focus
group stated, "The worst part about it is the emotional
strain that was put on everyone around me." The financial
strain triggered by the medical expenses also creates a
stressful environment for many patients. One patient
stated, "There [are] times that I won't go to the doctor
because I know that I can't afford to go."
Functional health
Patients reported a strong relationship between the symp-
toms of ITP and functional health limitations particularly
with respect to the need to limit daily activities (see Table
2d). For instance, patients reported that their activities
were limited because of fatigue. "I get so tired I can't even
move." or "When I've been on my legs too long, they start
cramping" were just two of the comments made by focus
group participants. Difficulty sleeping was also reported
by many focus group patients, with one patient stating, "I
never sleep through the night. It's just restlessness and
you're not comfortable."
Work life
As indicated in Table 2e, the majority of the patients in the
focus groups indicated that ITP had interfered with their
ability to work, and some individuals mentioned that ITP
had hindered their ability to advance in their career. Many
patients reported that they took time off or quit working
entirely due to the symptoms or treatment of ITP. A
female patient stated, "I loved working but the fact that I
have to sleep when I'm not working makes me want to
work less so that I can do something besides sleep."
Patients in CA and NY reported that they had experienced
a change in their desire or reason for going to work. For
instance, one patient stated, "Now I'm a technical writer,
which has no [bleeding] risk at all. I just sit at the compu-
ter and type. I really don't like it, but I don't have too
many options." However, no patients in the OK focus
groups mentioned a change in attitude toward work or
work environments.
Social and leisure activities
Table 2f shows that patients with ITP report suffering from
feelings of social embarrassment due to visible signs of the
disease (bruising) and that their involvement in sports or
other physical activities is limited. Testimony such as "My
bruising bothers me especially in the summertime when I
can't [go swimming] because I'm always bruising and peo-
ple look at you funny" and "I've had co-workers and
friends ask me if my husband was beating me" were
recorded. Patients also reported that symptoms of ITP pre-
vent them from participating in leisure activities such as
exercise, gardening, and travel. A female patient com-
mented, "My friends think I'm crazy because I won't go
[to] the movies with them on a Friday night. I'm just so
exhausted when I get home. I don't have the energy to get
dressed and go to a movie."
Reproductive health
Both male and female participants in the focus groups
reported decreased libido due to the symptoms of ITP and
the side effects of treatment. A male participant stated,
"Now on the prednisone my desire has gone down con-
siderably. I swear I used to be sexually active 4 or 5 nights
a week, now it's once or twice a month." Female partici-
pants also reported bruising and bleeding as a result of
sexual intercourse.
The numerous publications dealing with pregnancy and
obstetrics indicate that ITP greatly affects women, particu-
larly with respect to child bearing. Information from the
focus groups highlighted the exacerbation of menstrual
bleeding (both severity and duration) in women with ITP.
In addition, some women also mentioned anxiety over
the potential inability to bear children. However, the liter-
ature suggests that the outcome of pregnancy in women
with ITP is generally good, if close monitoring and treat-
ment is provided to expectant mothers and infants [41].
One woman gave the following anecdote that was charac-
teristic of other reports: "When I first got ITP I thought
that I couldn't have children. And then my gynecologist
told me that I could have children while taking pred-
nisone. All those years my hematologist made me think I
couldn't have children."
Discussion
The clinical manifestations of ITP and its management
affect patients' everyday activities and well-being. Our
research aimed to propose a conceptual model that
describes the impact of ITP and its treatments on patients'
HRQoL by using information gathered from the pub-
lished literature and from the patient perspective reported
in focus groups. Qualitative methods were used to group
the patient reports into one biological variable, two main
determinants, and five conceptual domains of HRQoL rel-
evant to patients with ITP.
A conceptual model providing a proposed causal linkage
with HRQoL can be useful for several reasons. To begin, itPage 10 of 14
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pathway for how benefits and risks of new treatments may
impact the lives of ITP patients. Also this pathway will
assist researchers in selecting (or developing) appropriate
outcome measures to evaluate a treatment's efficacy.
Although the etiology of ITP is poorly understood,
patients with low platelet counts are at greater risk of com-
plications. Also, platelet counts, with or without the pres-
ence of symptoms, can dictate whether to treat ITP. It is to
be expected, then, that in the focus groups, patients
reported keen awareness and close monitoring of the ups
and downs of their platelet counts. The emphasis placed
on the fluctuations in this clinical marker appears to cause
nearly as much anxiety for the patient as the actual disease
symptoms, particularly for patients that have undergone
splenectomy with the hope of full permanent remission.
Further, the focus group patients reported some distress
about the confusion surrounding the disease, specifically
with relation to childbearing. Future efforts to educate
those affected by the disease could reduce the discrepancy
between the perceptions and the medical facts.
Symptoms of the disease were found to be important fac-
tors characterizing patient well-being. According to
patients, the bruising and bleeding resulting from ITP sig-
nificantly worsen HRQoL. In addition, since fatigue sub-
stantially hindered patients' ability to perform their daily
activities, the management of fatigue could potentially
improve overall HRQoL. However, despite our finding
that over 90% of the patients in the CA and OK focus
groups mentioned fatigue, currently fatigue is not suffi-
ciently often considered by clinicians who manage per-
sons with ITP. In fact, fatigue is seldom recorded as an
adverse event in clinical trials of ITP patients.
In addition to potentially severe clinical outcomes, the
effects of the various ITP treatments impact multiple facets
of the patients' lives. However, the adverse effects of corti-
costeroids, such as weight gain and mood swings, were
most emphasized during the focus group discussions.
Patients reported side effects of other treatments, such as
hair loss and susceptibility to infection, less frequently.
Since treatment with corticosteroids is usually first-line
therapy for patients with ITP, it is likely that all patients in
the focus groups had received treatment with corticoster-
oids at some time.
Patients reported some concern over increased suscepti-
bility to infection as a result of splenectomy. These
reported fears may seem unfounded when reviewing
some reports of high success rates (i.e., increased platelet
counts) one year following splenectomy [21,26]. How-
ever, some evidence suggests that longer-term outcomes
may not be as favorable bringing to question the risk-ben-
efit ratio of splenectomy in the face of all the anxiety.
Kojouri, et al. found that 66% of the patients had a com-
plete response to splenectomy, defined as achievement
and maintenance of a normal platelet count, (> 150 × 109/
L or as defined in the original report and > 100 × 109/L for
all measurements 30 days or longer after splenectomy,
and with no additional treatment for ITP, except for the
tapering of perioperative glucocorticoids or other treat-
ments) with a median follow-up of 29 months. They also
found surgical complication rates of 12.9% and 9.6% for
laparotomy and laparoscopic splenectomy, respectively.
However, they acknowledge that the follow-up duration
may not have been long enough to provide a valid assess-
ment of long-term risks associated with splenectomy,
especially since relapse rates increase with duration of fol-
low up [13]. Portielje, et al. found that, of those patients
who had experienced complete response (platelet count
>100 × 109/L) within 2 years of diagnosis, 45% had expe-
rienced at least one ITP-related hospital admission in the
10-year follow-up period [49]. McMillan and Durette
studied 105 chronic ITP adults who were refractory to
splenectomy. During the median follow-up period of 110
months, 6 patients (5.6%) died of treatment-related com-
plications (including sepsis associated with long periods
of immunosuppression, postoperative pancreatitis, and
transfusion-related hepatitis C) [23].
It is worth noting that just as the model provides a path-
way for describing how negative outcomes or adverse
events of treatment affect the patients' HRQoL; the model
also holds in the case of positive effects of treatment.
Although it was not emphasized explicitly in the focus
groups, any effects of a particular treatment that patients
perceive as positive (e.g., a stable platelet count, increase
in energy and vitality, decrease in anxiety) would likely
improve the domains of HRQoL.
ITP researchers have acknowledged the value that PRO
measures would bring to understanding the signs and
symptoms of ITP and its treatments effects on HRQoL.
After conducting a literature review aimed at assessing var-
iability and terminology used in the diagnosis and treat-
ment of ITP, Ruggeri, et al. suggested that further studies
consider the effect of treatment options on quality of life
evaluations as well as treatment effects on platelet counts
[54]. Bussel, et al. also recognized that improved treat-
ment outcomes with new treatments can have an effect on
patient HRQoL [34]. Our literature searches yielded only
four instances in which a questionnaire was used to assess
quality of life [17,32,56,57]. The PRO endpoints pursued
in the studies were consistent with the concerns voiced by
the patients in the focus groups, e.g. fear of bleeding and
extreme fatigue.Page 11 of 14
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particularly useful when comparing HRQoL outcomes of
treatments that may have differential impacts on HRQoL
or when some aspects of HRQoL may be improved at the
expense of others. Our proposed conceptual model delin-
eates concepts that may be considered in a PRO question-
naire to assess HRQoL changes in persons with ITP. Most
of these concepts are included in the ITP-PAQ; any differ-
ences between the model and the ITP-PAQ reflect that the
questionnaire was developed for use in clinical trials and
could not contain all issues that may be relevant to
patients. The model will also assist in the selection of
items, scales, and/or questionnaires that may be appropri-
ate to utilize when assessing HRQoL in ITP patients.
This research has some limitations. For one, the concep-
tual model focuses specifically on the relationship
between symptoms, side-effects, and HRQoL and did not
address other concepts such as treatment satisfaction,
treatment decision-making, and medication compliance.
Research looking into the roles of these other outcomes
on patient HRQoL in ITP may be important.
The decision to use focus groups to gather patient contri-
butions also created limitations. For instance, only Eng-
lish-speaking patients in the US were sampled; therefore
the conceptual model may need further testing to be gen-
eralizable in other populations. The time commitment
required for focus group participation and the use of an
honorarium as an incentive for participating may have
introduced a self-selection bias into the sample popula-
tion. Also, the entry criteria for participation in the focus
groups were very broad. No strata were used to guarantee
a distribution in severity of disease, success of treatment,
duration of disease, or age. All patients were recruited by
physicians from tertiary care centers that tend to treat
more severe or refractory patients. Therefore, this sample
may be biased by over representing patients that are, in
general, more ill or more aware of their illness. It is worth
noting that although group interaction can stimulate par-
ticipant ideas that might not have been available on an
individual basis, it may also lead to overemphasis of the
opinions of the groups' participants. For this reason, it is
critical to the success of a focus group to have a highly
experienced moderator guide the discussion.
Finally, because we could not match demographic or clin-
ical history to individual focus group participants, it was
not possible to distinguish whether the concepts affected
some patients more than others. In particular, gender and
age may play an important role in determining the
HRQoL of adult patients living with chronic ITP. Further
studies on the varying severity and progress of ITP may
lead to slightly different conclusions regarding the path-
way from platelet counts through signs and symptoms
and HRQoL domains to overall HRQoL. However, the
intent of this research was to develop a broad conceptual
model.
Future research will build on the findings of this study.
The sample size needed for qualitative research is deter-
mined by the concept of theoretical saturation. In order to
achieve saturation, data must be collected until no new
information is obtained. For this model our empirical
data source, the existing transcripts of contributions from
23 patients, was not designed to reach saturation of
themes or concepts. Researchers may wish to collect addi-
tional patient data either in focus groups or individual
interviews to reach saturation on all areas of interest.
While the literature searches yielded several question-
naires that have been used to assess HRQoL in persons
with ITP, only the ITP-PAQ, developed based on the feed-
back from these very focus groups of ITP patients, was
designed and validated in patients with ITP. The ITP-PAQ
covers many of the themes identified in our conceptual
model for ITP, however other concepts important to
patients, e.g. ability to perform daily activities, feelings of
social isolation, inability to travel, financial stress, and
reduction in libido, are not included in the ITP-PAQ.
Patient-reported data captured with questionnaires such
as the ITP-PAQ may be used to refine the conceptual
model presented here. We expect further targeted
research, in the style of Moore, et al. [60], to be used to test
the relationships proposed in the ITP conceptual model,
e.g., observing the changes in HRQoL of a subset of
patients with a specific treatment or patients with a spe-
cific symptom.
Conclusion
A conceptual model of health-related quality of life for
patients with ITP consisting of two main determinants
was developed: (1) signs and symptoms; and, (2) treat-
ment effects; and five HRQoL domains: (1) emotional
health, (2) functional health, (3) work life, (4) social and
leisure activities, and (5) reproductive health. This con-
ceptual model should help to inform the evaluation of
therapeutic strategies for ITP.
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